Asthma breakthrough? new study tests cutting back on meds with benralizumab

NCT ID NCT06465485

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-acting bronchodilators while staying on benralizumab. The goal is to see if they can maintain asthma control with fewer pills or inhalers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Benralizumab (Fasenra)
What this could lead to: If successful, this could show that benralizumab helps people with severe eosinophilic asthma safely reduce their daily controller medications while still keeping asthma under control.
What could go wrong: This is a single-arm study (no placebo group), so results may be less definitive. It is also limited to Chinese patients, so findings may not apply to other populations. Reducing medication could risk asthma flare-ups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE EOSINOPHILIC ASTHMA

Contacts and locations

Locations

Research Site

Beijing, 100020, China
Research Site

Beijing, 100029, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Changsha, 410005, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410011, China
Research Site

Chengdu, 610014, China
Research Site

Chengdu, 610021, China
Research Site

Chengdu, 610041, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 402260, China
Research Site

Guangzhou, 510163, China
Research Site

Guangzhou, 510280, China
Research Site

Guangzhou, 510515, China
Research Site

Guangzhou, 510630, China
Research Site

Guilin, 541001, China
Research Site

Guiyang, 510630, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310009, China
Research Site

Hefei, 230061, China
Research Site

Hefei, 230601, China
Research Site

Hohhot, 010010, China
Research Site

Hohhot, 10050, China
Research Site

Huzhou, 313003, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250014, China
Research Site

Jinan, 250030, China
Research Site

Kunming, CN-650034, China
Research Site

Lanzhou, 730000, China
Research Site

Luoyang, 471000, China
Research Site

Nanjing, 210029, China
Research Site

Nanjing, 211100, China
Research Site

Nanning, 530021, China
Research Site

Ningbo, 315010, China
Research Site

Qingdao, 266042, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200065, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, 200092, China
Research Site

Shenyang, 110001, China
Research Site

Shenyang, 110004, China
Research Site

Shenzhen, 518001, China
Research Site

Shenzhen, 518036, China
Research Site

Shenzhen, 518039, China
Research Site

Shenzhen, 518101, China
Research Site

Shijiazhuang, 054001, China
Research Site

Shijiazhuang, 50051, China
Research Site

Suzhou, 215004, China
Research Site

Suzhou, 215006, China
Research Site

Taiyuan, 030001, China
Research Site

Taiyuan, 030032, China
Research Site

Tangshan, 63000, China
Research Site

Tianjin, 300050, China
Research Site

Tianjin, 300192, China
Research Site

Tianjin, 300222, China
Research Site

Weifang, 261000, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430010, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430060, China
Research Site

Wuhu, 241000, China
Research Site

Xi'an, 710061, China
Research Site

Xi'an, 710068, China
Research Site

Xi'an, 710100, China
Research Site

Xiamen, 361004, China
Research Site

Xinxiang, 453100, China
Research Site

Xuzhou, 221009, China
Research Site

Yangzhou, 225001, China
Research Site

Zhangzhou, 363099, China
Research Site

Zhengzhou, 450003, China
Research Site

Zhengzhou, 450007, China
Research Site

Zhengzhou, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.